A Case of Visual and Auditory Hallucinations during Intravenous Voriconazole Therapy.
- Author:
Min Ju KIM
1
;
Moon Hee YOUN
;
Sang Bae KIM
;
Yul Hee CHO
;
Min Young LEE
;
Sung Yeon CHO
;
Jae Cheol KWON
;
Si Hyun KIM
;
Yoo Jin KIM
;
Dong Gun LEE
Author Information
- Publication Type:Case Report
- Keywords: Voriconazole; Hallucinations; Drug Monitoring; Therapeutic
- MeSH: Adult; Alleles; Amphotericin B; Aspergillosis; Deoxycholic Acid; Drug Combinations; Drug Monitoring; Fever; Genotype; Hallucinations; Humans; Leukemia, Myeloid, Acute; Plasma; Pneumonia; Pyrimidines; Triazoles
- From:Infection and Chemotherapy 2011;43(5):421-424
- CountryRepublic of Korea
- Language:Korean
- Abstract: Voriconazole is a triazole with broad spectrum antifungal activity, and it is currently considered to be the first-line agent for the treatment of invasive aspergillosis. We report here on a case of visual and auditory hallucinations during intravenous treatment with voriconazole in association with a high trough level. A 28-year-old man with acute myelogenous leukemia was admitted for re-induction remission chemotherapy. During the persistent neutropenic fever, intravenous voriconazole was administered for the suspected invasive fungal pneumonia. He began to have visual hallucinations on the 1st day and auditory hallucinations on the 3rd day of voriconazole therapy. The plasma peak and trough concentration levels of voriconazole were 9.9 and 7.4 microg/ml, respectively, on the 3rd day. The hallucinations resolved after changing to amphotericin B deoxycholate, and the plasma concentration of voriconazole dropped to less than 0.5 microg/ml. The genotype of the CYP2C19 alleles was classified as a heterozygous extensive metabolizer. We suggest that therapeutic drug monitoring of voriconazole is indicated for a case that is suspicious for a voriconazole-related adverse event.
